# US 6,388,132 B1 · Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,388,132 B1
- Document ID: US6388132B1
- Status: Granted
- Kind: B1
- Application number: 09/694,783
- Filed: 2000-10-24
- Granted: 2002-05-14
- Earliest claimed: 1995-03-10
- Assignees: G. D. Searle & Co.
- Inventors: Daniel P Getman; Gary A DeCrescenzo; John N Freskos; Michael L Vazquez; James A Sikorski; Balekudru Devadas; Srinivasan Raj Nagarajan; David L Brown; Joseph J McDonald
- Web page: https://patentgrep.com/patent/US6388132B1

## CPC

- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- C07K 14/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- C07K 16/1207: {from Spirochaetales (O), e.g. Treponema, Leptospira}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

## Claims

### Claim 1

Compound represented by the formula:
or a pharmaceutically acceptable salt or ester thereof, wherein
R1 represents alkyl of 1-5 carbon atoms or alkynyl of 2-5 carbon atoms;
R4 represents aryl; and
R13 represents aralkyl, cycloalkyl, or alkoxyalkyl radicals.

### Claim 2 (depends on 1)

Compounds of claim 1, or a pharmaceutically acceptable salt, or ester thereof, wherein
R1 represents tert-butyl, iso-propyl, sec-butyl, or CH≡CHCH2—;
R4 represents phenyl, 4-methoxyphenyl, or 2-naphthyl; and
R13 represents benzyl, cyclopropyl, or methoxyethyl.

### Claim 3 (depends on 1)

Compound of claim 1, or a pharmaceutically acceptable salt, or ester thereof, wherein
R1 represents tert-butyl;
R4 represents optionally substituted phenyl; and
R13 represents optionally substituted benzyl.

### Claim 4 (depends on 1)

Compound of claim 1 wherein said pharmaceutically acceptable salt is hydrochloric acid salt, sulphuric acid salt, phosphoric acid salt, oxalic acid salt, maleic acid salt, succinic acid salt, citric acid salt or methanesulfonic acid salt.

### Claim 5 (depends on 4)

Compound of claim 4 wherein said pharmaceutically acceptable salt is hydrochloric acid salt, oxalic acid salt, citric acid salt or methanesulfonic acid salt.

### Claim 6 (depends on 1)

Composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

Method of inhibiting a retroviral protease comprising administering an effecive amount of a compound of claim 1.

### Claim 8 (depends on 6)

Method of treating a retroviral infection comprising administering an effective amount of a composition of claim 6.

### Claim 9 (depends on 1)

Method of preventing replication of a retrovirus comprising administering an effective amount of compound of claim 1.
